Literature DB >> 10079371

Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.

T M Clay1, M C Custer, P J Spiess, M I Nishimura.   

Abstract

The purpose of this review is to illustrate some of the technical and biological hurdles that need to be addressed when developing new gene therapy based clinical trials. Gene transfer approaches can be used to "mark" cells to monitor their persistence in vivo in patients, to protect cells from toxic chemotherapeutic agents, correct a genetic defect within the target cell, or to confer a novel function on the target cell. Selection of the most suitable vector for gene transfer depends upon a number of factors such as the target cell itself and whether gene expression needs to be sustained or transient. The TCR gene transfer approach described here represents one innovative strategy being pursued as a potential therapy for metastatic melanoma. Tumor reactive T cells can be isolated from the tumor infiltrating lymphocytes (TIL) of melanoma patients. A retroviral vector has been constructed containing the T cell receptor (TCR) alpha and beta chain genes from a MART-1-specific T cell clone (TIL 5). Jurkat cells transduced with this virus specifically release cytokine in response to MART-1 peptide pulsed T2 cells, showing that the virus can mediate expression of a functional TCR. HLA-A2 transgenic mice are being used to examine whether transduced bone marrow progenitor cells will differentiate in vivo into mature CD8+ T cells expressing the MART-1-specific TCR. Expression of the human TCR alpha and beta chain genes has been detected by RT-PCR in the peripheral blood of HLA-A2 transgenic mice reconstituted with transduced mouse bone marrow. Expression of the TIL 5 TCR genes in the peripheral blood of these mice was maintained for greater than 40 weeks after bone marrow reconstitution. TIL 5 TCR gene expression was also maintained following transfer of bone marrow from mice previously reconstituted with transduced bone marrow to secondary mouse recipients, suggesting that a pluripotent progenitor or lymphocyte progenitor cell has been transduced.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10079371     DOI: 10.1053/paor.1999.0003

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  68 in total

1.  Phase I evaluation of interleukin-2-transfected irradiated allogeneic melanoma for the treatment of metastatic melanoma: appendix 1: protocol.

Authors:  T K Das Gupta; E P Cohen; J M Richards
Journal:  Hum Gene Ther       Date:  1997-09-20       Impact factor: 5.695

2.  Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins.

Authors:  R A Morgan; R Walker
Journal:  Hum Gene Ther       Date:  1996-06-20       Impact factor: 5.695

3.  A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease.

Authors:  T Flotte; B Carter; C Conrad; W Guggino; T Reynolds; B Rosenstein; G Taylor; S Walden; R Wetzel
Journal:  Hum Gene Ther       Date:  1996-06-10       Impact factor: 5.695

4.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production.

Authors:  A D Miller; C Buttimore
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

5.  An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT (V) (HIV-1IIIBenv/rev retroviral vector) in HIV-1-infected subjects.

Authors:  R Haubrich; J A McCutchan; R Holdredge; L Heiner; J Merritt; B Merchant
Journal:  Hum Gene Ther       Date:  1995-07       Impact factor: 5.695

6.  Recombinant adeno-associated virus for muscle directed gene therapy.

Authors:  K J Fisher; K Jooss; J Alston; Y Yang; S E Haecker; K High; R Pathak; S E Raper; J M Wilson
Journal:  Nat Med       Date:  1997-03       Impact factor: 53.440

7.  Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2.

Authors: 
Journal:  Hum Gene Ther       Date:  1992-02       Impact factor: 5.695

8.  Retroviral-mediated expression of an MHC class I-restricted T cell receptor in the CD8 T cell compartment of bone marrow-reconstituted mice.

Authors:  R J Pogulis; M J Hansen; L R Pease
Journal:  Hum Gene Ther       Date:  1998-10-10       Impact factor: 5.695

9.  Retroviral mediated transfer of the cDNA for human glucocerebrosidase into hematopoietic stem cells of patients with Gaucher disease. A phase I study.

Authors:  C Dunbar; D Kohn
Journal:  Hum Gene Ther       Date:  1996-01-20       Impact factor: 5.695

10.  Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus.

Authors:  A D Miller; J V Garcia; N von Suhr; C M Lynch; C Wilson; M V Eiden
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

View more
  8 in total

1.  Adoptive immunotherapy of cancer: Gene transfer of T cell specificity.

Authors:  Amir A Al-Khami; Shikhar Mehrotra; Michael I Nishimura
Journal:  Self Nonself       Date:  2011-04-01

2.  TCR mispairing in genetically modified T cells was detected by fluorescence resonance energy transfer.

Authors:  Hongwei Shao; Wenfeng Zhang; Qinglian Hu; Fenglin Wu; Han Shen; Shulin Huang
Journal:  Mol Biol Rep       Date:  2010-04-06       Impact factor: 2.316

3.  Adoptive T-cell Immunotherapy: Perfecting Self-Defenses.

Authors:  Raphaëlle Toledano Zur; Galit Adler; Katerina Shamalov; Yair Tal; Chen Ankri; Cyrille J Cohen
Journal:  Exp Suppl       Date:  2022

Review 4.  Development and clinical translation of ex vivo gene therapy.

Authors:  Xiaomo Wu; Xiaorong He; Fahui Liu; Xiaochang Jiang; Ping Wang; Jinyan Zhang; Ju Jiang
Journal:  Comput Struct Biotechnol J       Date:  2022-06-11       Impact factor: 6.155

Review 5.  Hematopoietic stem cells for cancer immunotherapy.

Authors:  Eric Gschweng; Satiro De Oliveira; Donald B Kohn
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells.

Authors:  Francesca Giannoni; Cinnamon L Hardee; Jennifer Wherley; Eric Gschweng; Shantha Senadheera; Michael L Kaufman; Rebecca Chan; Ingrid Bahner; Vivian Gersuk; Xiaoyan Wang; David Gjertson; David Baltimore; Owen N Witte; James S Economou; Antoni Ribas; Donald B Kohn
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

7.  High-titre retroviral vector system for efficient gene delivery into human and mouse cells of haematopoietic and lymphocytic lineages.

Authors:  Chengxiang Wu; Yuanan Lu
Journal:  J Gen Virol       Date:  2010-04-21       Impact factor: 3.891

8.  T cell avidity and tumor recognition: implications and therapeutic strategies.

Authors:  Mark D McKee; Jeffrey J Roszkowski; Michael I Nishimura
Journal:  J Transl Med       Date:  2005-09-20       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.